QIAGEN Q4 Profit Decreases - Quick Facts

(RTTNews) - QIAGEN N.V. (QGEN) reported fourth-quarter net income to the owners of $25.84 million or $0.11 per share, compared to $60.15 million or $0.25 per share, prior year. Adjusted earnings per share was $0.25, for the quarter.

On average, 19 analysts polled by Thomson Reuters expected the company to report profit per share of $0.30 for the quarter. Analysts' estimates typically exclude special items.

Net sales decreased to $360.41 million from $361.09 million last year. Adjusted net sales were $360.8 million, for the quarter. Analysts expected revenue of $367.67 million for the quarter.

QIAGEN expects to deliver higher adjusted net sales and adjusted earnings in 2015 at constant exchange rates (CER) with above-market sales growth from the current core portfolio - led by the growth drivers - well exceeding the final year of significant headwinds from reduced U.S. sales of HPV products.

For the full year, the company expects adjusted net sales to rise approximately 4% CER. Adjusted earnings per share are expected to be approximately $1.16-1.18 CER. Based on current exchange rates, QIAGEN expects the movements of the U.S. dollar, its reporting currency, against various currencies to have an adverse impact on adjusted sales results, and to a lesser degree on adjusted EPS results, and a relatively modest impact on the adjusted operating income margin. Analysts expect the company to report full year earnings per share of $1.16.

For the first quarter of 2015, QIAGEN expects adjusted net sales growth of approximately 2% CER, and adjusted EPS of approximately $0.22-0.23 CER. QIAGEN expects currency movements to have an adverse impact of approximately seven percentage points on reported sales growth and approximately $0.01 per share on adjusted EPS. Analysts expect the company to report first-quarter earnings per share of $0.25.